Olema Pharmaceuticals (OLMA) Stock Statistics & Valuation Metrics

Olema Pharmaceuticals has a market cap or net worth of $2.23B. The enterprise value is $514.84M.

Olema Pharmaceuticals has 78,659,920 shares outstanding. The number of shares has decreased by -2.65% in one year.

Olema Pharmaceuticals’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -34.66%.

The current PE Ratio of Olema Pharmaceuticals is ―. Olema Pharmaceuticals’s PEG ratio is -0.94.

In the last 12 months, Olema Pharmaceuticals had revenue of 0.00 and earned -129.47M in profits. Earnings per share was -2.20.

In the last 12 months, operating cash flow was -134.67M and capital expenditures 0.00, giving a free cash flow of -134.67M billion.

Olema Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Olema Pharmaceuticals upcoming earnings date is Mar 2, 2026, After Close (Confirmed).

Olema Pharmaceuticals as a current ratio of 10.50, with Debt / Equity ratio of 0.48%

In the past 12 months, Olema Pharmaceuticals has paid 0.00 in taxes.

Olema Pharmaceuticals EV to EBITDA ratio is -1.44, with an EV/FCF ratio of -1.96.

Olema Pharmaceuticals has $328.96M in cash and marketable securities with $4.48M in debt, giving a net cash position of $324.48M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Olema Pharmaceuticals is $36.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy